Total Utang marang Modal Bicara Bio (BCAX)

Bicara Therapeutics - logo grafis emiten BCAX

Bicara Therapeutics Inc. (BCAX) plans to generate revenue through the sale of innovative antibodies targeting head and neck cancer, although the targeted therapy sector carries immense risks of failure. The trend of the company's total liabilities-to-equity ratio on the GURU.Markets chart allows for an assessment of financial stability, where the value of 0.00 reflects this status. Currently, breakthrough developments are undergoing clinical trials, remaining at the beginning of their potential cycle.

bicara.com (BCAX): Rasio Utang marang Ekuitas saka 14.09.2024 nganti 31.10.2026

Rincian metrik lan analitis perusahaan Bicara Corp (BCAX)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Bicara Therapeutics|BCAX - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Bicara Therapeutics|BCAX - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Bicara Therapeutics|BCAX - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku bicara.com|BCAX - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Bicara Therapeutics Inc.|BCAX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Bicara Therapeutics Inc.|BCAX - Kewajiban utang agregat|Utang marang nilai buku Bicara Therapeutics|BCAX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Bicara Therapeutics|Indikator likuiditas cepet bicara.com
- data bathi resik lan rasio valuasi:
BCAX - Bathi resik
Pambiji fundamental perusahaan:Bicara Therapeutics
Produk dadi Bicara Therapeutics Inc.

The market evaluates Bicara Therapeutics Inc. (BCAX) through the lens of capital management efficiency within the context of outsourced drug development. This ratio measures the proportion of borrowed funds relative to equity, determining the company's degree of financial leverage. By analyzing the total financial debt-to-equity ratio, an investor can discern the business's dependence on external creditors. For a model based on contract research, a low level of indebtedness minimizes risks during operational delays. The stable trend of this metric confirms the resilience of the balance sheet.

Analisis pesaing Bicara Therapeutics Inc.

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Personalis - Total Utang marang Modal|Erasca Inc (ERAS) - Rasio Total Utang marang Ekuitas|DCTH: Total Utang marang Modal|Utang marang Modal Y-mAbs Corp (YMAB)|Utang marang Ekuitas Aura Biosciences, Inc.|CADL: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas ARAY (Accuray)|SLS (sellaslifesciences.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ACTU (Actuate Therapeutics, Inc)|CTOR - Rasio Total Utang marang Ekuitas|HURA: Rasio Total Utang marang Ekuitas|TARA - Total Utang marang Modal|Fate Therapeutics (FATE) - Utang marang Ekuitas|Aadi Bioscience - Rasio Kabeh Utang marang Dana Pribadi|TCRX (TScan Therapeutics Inc) - Total Utang marang Modal|Utang marang Modal Champions Oncology Corp CSBR|Total Utang marang Modal XBIT|Utang marang Ekuitas CVM (cel-sci.com)|Total Utang marang Modal OSTX (OS Therapies)|Koefisien Total Utang marang Modal radiopharmtheranostics.com (RADX)|Artiva - Total Utang marang Modal|Adlai Nortye Ltd. (ANL) - Rasio Total Utang marang Ekuitas|VERU: Total Utang marang Modal|tempesttx.com (TPST) - Total Utang marang Modal|Utang marang Ekuitas Xilio Therapeutics Inc|RENB: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal MURA|Total Utang marang Modal kairospharma.com (KAPA)|OnKure Therapeutics - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi GDTC|CRIS: Rasio Total Utang marang Ekuitas|Apollomics, Inc. - Utang Agregat marang Modal|THAR: Total Utang marang Modal|Advanced Biomed - Rasio Kabeh Utang marang Dana Pribadi|GNPX (Genprex, Inc.) - Total Utang marang Modal|Utang marang Modal Calidi Bio CLDI|Utang marang Ekuitas Sunshine Biopharma, Inc. (SBFM)|XBIO (xeneticbio.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLRX (Salarius)|Total Utang marang Modal Kitov Pharma PPBT|AONC - Utang marang Ekuitas|Utang Agregat marang Ekuitas BGNE|CKPT: Total Utang marang Modal|Utang marang Modal elevationoncology.com (ELEV)|Rasio Total Utang marang Ekuitas ICAD|Total Utang marang Modal Ikena|Rasio Total Utang marang Ekuitas NTBL (Notable Labs, Ltd.)|Utang Agregat marang Modal VIRX|Total Utang marang Modal MOR (MorphoSys)|Koefisien Total Utang marang Modal NAYA Biosciences Inc (NAYA)|Ascentage Pharma Group Ltd - Total Utang marang Modal